Galimedix Outlines Alzheimer's Drug Phase 2a Plans

The Phase 2 private biotech company detailed its planned GAL-101 development program at the CTAD 2026 conference in Boston.

Updated on Nov. 16, 2026 in Alzheimer’s

Galimedix Outlines Alzheimer's Drug Phase 2a Plans

Galimedix Therapeutics presented new details on its planned Phase 2a development program for GAL-101 in Alzheimer's disease at the CTAD 2026 conference. The SAPHARY trial is registered as NCT07789873 and will be a 28-day, double-blind, randomized, multicenter, placebo-controlled study enrolling 100 patients with mild to moderate Alzheimer's disease.

Why it matters

Alzheimer's disease is highly heterogeneous and urgently needs therapies that can slow or stop memory and cognition loss. GAL-101 targets misfolded amyloid beta monomers to prevent formation of toxic oligomers and protofibrils, and Phase 1 testing showed it was safe and well tolerated when taken orally.

The SAPHARY Phase 2a trial (NCT07789873) will enroll 100 patients over 28 days, with a placebo control arm. Whether GAL-101 demonstrates efficacy in mild to moderate Alzheimer's remains unknown until the trial reports.

The players

Galimedix Therapeutics, Inc.

A Phase 2 clinical-stage private biotechnology company headquartered in Kensington, Maryland, with a second site in Munich/Martinsried, Germany, developing GAL-101 for Alzheimer's disease.

The details

The SAPHARY trial will evaluate the safety, efficacy, and pharmacokinetics of oral GAL-101 salt, along with pharmacokinetic/pharmacodynamic parameters, exploratory EEG readouts, fluid biomarkers, and cognition endpoints. Galimedix also plans a proof-of-concept trial of GAL-101 in Down syndrome-associated Alzheimer's disease, and GAL-101 eyedrops are in the ongoing eDREAM Phase 2 study for dry age-related macular degeneration.

Timeline

  1. November 16, 2026: Galimedix announced presentation of its Phase 2a plans at CTAD 2026.

  2. November 16-19, 2026: CTAD 2026 conference held in Boston, MA.

Research Landscape

Galimedix's presentation at the 19th edition of the CTAD conference places GAL-101 within the annual forum where Alzheimer's clinical trial programs are reported to the research community. The SAPHARY design, which measures EEG and fluid biomarkers alongside cognition, reflects the biomarker-driven approach that has defined recent Alzheimer's trial development.

For people living with mild to moderate Alzheimer's disease, the SAPHARY trial represents an investigational option under study rather than an available treatment. Any future access would depend on trial results and regulatory review.

The takeaway

Investigational Alzheimer's therapies like GAL-101 are advancing through placebo-controlled trials, and readers should watch for SAPHARY efficacy results before drawing conclusions about benefit. Clinical trial registrations such as NCT07789873 make ongoing studies publicly searchable.

Further reading

For broader context on treatment research, see our Alzheimer's coverage.

Source note: This article includes information reported by The Manila times.